Enanta Pharmaceuticals (NASDAQ:ENTA) Receives “Market Outperform” Rating from JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reissued by equities research analysts at JMP Securities in a research note issued to investors on Friday, Benzinga reports. They presently have a $22.00 price target on the biotechnology company’s stock. JMP Securities’ price target indicates a potential upside of 111.95% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, August 6th. JPMorgan Chase & Co. cut their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. Finally, Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA traded down $0.09 during midday trading on Friday, reaching $10.38. 22,451 shares of the company’s stock were exchanged, compared to its average volume of 205,672. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $17.80. The business’s fifty day moving average price is $12.87 and its two-hundred day moving average price is $13.50. The stock has a market capitalization of $219.84 million, a PE ratio of -1.67 and a beta of 0.59.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.36. The firm had revenue of $17.97 million for the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.27) EPS. Analysts predict that Enanta Pharmaceuticals will post -5.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, insider Scott T. Rottinghaus sold 5,375 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the sale, the insider now owns 21,717 shares of the company’s stock, valued at $370,926.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the transaction, the insider now owns 21,717 shares in the company, valued at $370,926.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott T. Rottinghaus sold 4,299 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the sale, the insider now directly owns 23,988 shares in the company, valued at approximately $361,499.16. The disclosure for this sale can be found here. 13.64% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new position in Enanta Pharmaceuticals in the second quarter worth approximately $35,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Enanta Pharmaceuticals in the 1st quarter worth $118,000. Quest Partners LLC raised its position in shares of Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the period. Virtu Financial LLC purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at $191,000. Finally, Pennant Investors LP acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at $330,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.